Iscoms as Mucosal Vaccine Vectors
There is currently a great deal of interest in developing orally active synthetic vaccines containing recombinant proteins as protective antigens. However, purified proteins are poorly immunogenic in general and do not elicit the mucosal immunity essential for protecting against diseases of mucosal surfaces such as the intestine and respiratory tract (McGhee et al 1992). Indeed, the usual result of administering soluble proteins by the oral route is profound immunological tolerance which prevents systemic and local immune responses on subsequent exposure to the antigen (Mowat 1987). Thus there is a need for vectors that will avoid this phenomenon of oral tolerance and prime a full range of immune responses to orally administered protein antigens.
KeywordsOral Tolerance Systemic Immune Response Mucosal Immune Response Peritoneal Exudate Cell Oral Immunisation
Unable to display preview. Download preview PDF.
- Heeg, K., Kuon, W. and Wagner, H., 1991, Vaccination of Class I major histocompatibility complex (MHC)-restricted murine CD8+ cytotoxic T lymphocytes toward soluble antigen: immunostimulating complexes enter the Class 1 MHC-restricted antigen pathway and allow sensitization against the immunodominant peptide. Eur.J.Immunol., 21: 152.CrossRefGoogle Scholar
- Morein, B., Fossum, C., Lovgren, K. and Hoglund, S., 1990, The ISCOM-a modern approach to vaccines. Semin. Virol., 1: 49.Google Scholar
- Mowat, A. MeI. and Reid, G., 1994, The preparation of immune stimulating complexes (ISCOMS) as adjuvants for local and systemic immunisation with protein antigens. In; “Current Protocols in Immunology”, J.E. Coligan Kruisbeek, A.M., Margulies, D., Shevach, E. and Strober, W.v eds., John Wiley and Sons Inc, New York.Google Scholar